When was Freenome Health founded?

Freenome Health was founded in 2014 and became a unicorn in 2022.

Where is Freenome Health located?

Freenome Health is headquartered in United States. It is registered at MEDICITY - D6 BUILDING,1 THANE ROAD,NOTTINGHAM,UNITED KINGDOM,NG90 6BH.

How many employees does Freenome Health have?

As of Mar 31, 2026, the latest employee count at Freenome Health is 393.

Is Freenome Health a funded company?

Freenome Health is a funded company, having raised a total of $1.35B across 8 funding rounds to date. The company's 1st funding round was a $700K Grant (prize money) round, raised on Jan 08, 2014.

How much is Freenome Health worth?

The latest valuation of Freenome Health is $1.5B as of Nov 22, 2021.

When was the latest funding round of Freenome Health?

Freenome Health's latest funding was a $254M Series E round on Feb 15, 2024, with participation from 20 investors.

Is Freenome Health a Genomics company?

The primary sectors of Freenome Health are Genomics, Oncology and Gastroenterology.

Where does Freenome Health rank among its competitors?

Freenome Health ranks 2nd amongst 71 active competitors, of which 22 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Magentiq Eye, which secured an undisclosed amount in Jul, 2025.

Who are the top competitors of Freenome Health?

Freenome Health's top competitors include Geneoscopy, Magentiq Eye and Angle. Among them, Magentiq Eye secured the most recent funding round in July, 2025.

Freenome Health - 2026 Company Profile, Team, Funding & Competitors

Freenome Health is a series E company based in United States, founded in 2014 by Charles Roberts, Riley Ennis and Gabriel Otte. It operates as a Provider of a deep learning platform for detecting circulating cancer-related markers. Freenome Health has raised $1.35B in funding from investors like Andreessen Horowitz, Roche and RA Capital Management, with a current valuation of $1.5B. The company has 71 active competitors, including 22 funded and 11 that have exited. Its top competitors include companies like Geneoscopy, Magentiq Eye and Angle.

Sectors and market segments that Freenome Health operate in

Freenome Health serves in the Life Sciences market segments.The primary business model of Freenome Health are:

Company Details

Provider of a deep learning platform for detecting circulating cancer-related markers. It offers a platform for detecting circulating cancer-related markers in patient blood samples. Its proprietary technology uses deep learning to detect cell-free DNA, immune cell fragments, and metabolic markers in the blood. It allows physicians to classify tumor types and develop treatment therapies for prostate, breast, colorectal, and lung cancer.

Website: www.freenome.com/
Social
Email ID: *****@freenome.com
Phone Number: +1 **********
Registered Address: MEDICITY - D6 BUILDING,1 THANE ROAD,NOTTINGHAM,UNITED KINGDOM,NG90 6BH

Key Metrics

Founded Year

2014

Location

United States

Stage

Series E

Total Funding

$1.35B in 8 rounds

Latest Funding Round

Series E, Feb 15, 2024, $254M

Post Money Valuation

$1.5B as on Nov 22, 2021

Investors

Andreessen Horowitz & 66 more

Ranked

2^nd among 71 active competitors

Employee Count

393 as on Mar 31, 2026

Investment & Acquisitions

Oncimmune

Similar Companies

Geneoscopy & 84 more

View Freenome Health's full profile

Freenome Health is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
FREENOME HOLDINGS INC. CIN: 81-2562661 , United States, Active	Jul 29, 2015	-	376 (As on Dec 31, 2024)	-
Freenome Limited CIN: 4606727 , United Kingdom, Active	Dec 02, 2002	-	16 (As on Dec 31, 2024)

Freenome Health has raised a total funding of $1.35B over 8 rounds. Its first funding round was on Jan 08, 2014. Its latest funding round was a Series E round on Feb 15, 2024 for $254M. 20 investors participated in its latest round. Freenome Health has 66 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Freenome Health:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 15, 2024	$254M	Series E	-	-	Roche	Squarepoint Capital Partners, BrightEdge, Andreessen Horowitz, Intermountain Ventures, ArrowMark Partners, Eventide Asset Management, RA Capital Management, Perceptive Advisors, Polaris Partners, Pura Vida Investments, DCVC, S32, Sands Capital, Cormorant Capital, Quest Diagnostics, Squarepoint Capital, ARK Venture Fund, Artis Ventures, Bain Capital Life Sciences
Jan 11, 2022	$290M	Series D	-	-	Roche	Andreessen Horowitz, American Cancer Society - North Carolina, ARK Investment Management, ArrowMark Partners, Artis Ventures, Bain Capital Life Sciences, Cormorant Capital, DCVC, Eventide Asset Management, Intermountain Healthcare, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Western & Southern Financial Group, India Code, Squarepoint Capital
Nov 22, 2021	$300M	Series D	$1.5B	-	Perceptive Advisors, RA Capital Management	BrightEdge, Andreessen Horowitz, Artis Ventures, Catalio Capital Management, Cormorant Capital, Bain Capital Life Sciences, Google Ventures, Polaris Partners, Ridgeback Capital Management, DCVC, Novartis, Janus Henderson Investors, Farallon Capital Management, Fidelity Investments, Kaiser Permanente, Sands Capital, Roche, Rock Springs Capital, Soleus Capital, ArrowMark Partners, HBM Healthcare Investments, Intermountain Healthcare, Logos, Suvretta Capital Management, Pura Vida Investments, byerscapital.com, T. Rowe Price, S32, Eventide Asset Management

Access funding benchmarks and valuations. Sign up today!

View details of Freenome Health's funding rounds and investors

The founders of Freenome Health are Charles Roberts, Riley Ennis and Gabriel Otte. Mike Nolan is the CEO of Freenome Health.

Here are the details of Freenome Health's key team members:

Charles Roberts: Co-Founder of Freenome Health and founder of 1 other company. They are also an angel investor in 1 startup.
Riley Ennis: Co-Founder & CPO of Freenome Health and founder of 1 other company.
Contact Info: 1 email address
Gabriel Otte: Former Co-Founder of Freenome Health.
Mike Nolan: CEO of Freenome Health.
Contact Info: 1 email address

View details of Freenome Health's Founder profiles and Board Members

Freenome Health's employee count trend

Freenome Health has 393 employees as of Mar 26. Here is Freenome Health's employee count trend over the years:

Employee count trend for Freenome Health

Uncover Freenome Health's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Freenome Health include Geneoscopy, Magentiq Eye and Angle. Here is the list of Top 10 competitors of Freenome Health, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	68/100
2nd	Freenome Health 2014, United States, Series E	Provider of a deep learning platform for detecting circulating cancer-related markers	$1.35B	Logos, RA Capital Management & 65 others	66/100
3rd	Magentiq Eye 2015, Haifa (Israel), Series A	Computer vision technology in endoscopic procedures	$100K	aMoon, Neuron.VC & 10 others	55/100
4th	Angle 1994, Surrey (Canada), Public	Developer of cancer cell capture and analysis equipment	-	WG Partners, Mercia & 1 others	55/100
5th	Miroculus 2014, San Francisco (United States), Acquired	Developer of MicroRNA profiling platform to detect genes in the sample	$48.4M	Cota Capital, Nazca & 11 others	54/100
6th	InterVenn 2017, San Francisco (United States), Series C	Provider of an AI-based clinical decision supporting tool for cancer detection and drug development	$251M	Genoa Ventures, SoftBank Group & 12 others	54/100
7th	Novigenix 2014, Epalinges (Switzerland), Series B	Developer of technology for cancer precision medicine	$20M	Eurostars, Europa	52/100
8th	Syrona Health 2018, Newcastle Upon Tyne (United Kingdom), Seed	Digital women's health management software for employers and individuals	$575K	Y Combinator, Bethnal Green Ventures & 19 others	50/100
9th	BiBB 2013, Lund (Sweden), Seed	Provider of biopsy instrument for the detection of cancerous tumors	$530K	EIC Fund, Almi Invest & 3 others	49/100
10th	Todos Medical 2009, Rehovot (Israel), Public	Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders	-	Lincoln Park Capital, Yozma & 2 others	48/100